Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

NCT02436759 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Acquired Blepharoptosis

Interventions

DRUG: RVL-1201
DRUG: RVL-1201 Vehicle Placebo

Sponsor

RVL Pharmaceuticals, Inc.